CFTR and cystic fibrosis: This approach proposes the advantage of directly selecting the best drug, or drug combination, for that individual and his/her combined mutations by pre-assessing the efficacy of CFTR-target drugs directly on specimens obtained from CF subject and as a consequence could diminish the approval of treatments that could be ineffective or harmful and create a high expectation to the patient and family members.